Hindson Benjamin J. sold $871K of TXG

Hindson Benjamin J. (See Remarks) sold 13,818 shares of 10x Genomics, Inc. (TXG) at $63.02 ($0.87M total) on 2026-08-24.

Original reporting
SEC EDGAR · Hindson Benjamin J.
Published Aug 26, 2026, 8:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TXG
Neutral
medium confidence
Mentioned
$TXG
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TXGNeutralLow
01

Why it matters

The insider sale is a routine transaction with limited market impact.

02

Market read

Small insider sale; unlikely to move the stock significantly.

03

Timing

post-market 2026-08-24

Relevance 5/10Novelty 4/10Timing: post-market 2026-08-24

Background

Form 4 filing discloses insider transaction for 10x Genomics.

Company-level read

Ticker impact

$TXGNeutralMedium confidence
Context

Officer/director Hindson sold 13,818 shares for $870,860, reducing his stake to 488,182 shares.

Expected impact

Potential modest downside pressure in short term.

Evidence & confidence

The sale size (~$0.87M) is small relative to market cap; impact likely limited.

Key entities

  • Hindson Benjamin J.

    Insider selling shares of TXG.

  • 10x Genomics, Inc.

    Biotech firm listed on NASDAQ under ticker TXG.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TXGMedAI 8/10

What 10x Genomics (TXG) Said on Its Q3 Earnings Call

10x Genomics (TXG) reported Q3 earnings, with consumables revenue up 5% YoY, driven by spatial products. Instrument revenue fell 43%, attributed to fewer units sold. Gross margin rose to 75% but is expected to decline in Q4 due to Atera instrument shipments. The company ended the quarter with $576M in cash. TXG also announced new software and clinical initiatives.

$TXGMed

Stifel raises 10X Genomics stock price target on Atera outlook

Stifel raised 10X Genomics' (TXG) price target to $68 from $50, citing strong Q3 results and increased Atera placement expectations. The stock has risen 347% over the past year, trading at $58.06. Analysts predict profitability this year with an EPS of $0.10, though the stock appears overvalued. Revenue was $150.66M, beating estimates, but margins are expected to decline due to Atera shipments.